Transcriptome changes during peanut oral immunotherapy and omalizumab treatment

Sofia Bjorkander1, Simon Kebede Merid1, David Brodin1, Josef Brandstrom1, Fredrik Fagerstrom-billai1, Marieke van der Heiden2, Jon Konradsen3, Michael Kabesch4, Cornelis Drumen5, Korneliusz Golebski5, Anke-Hilse Maitland - van der Zee6, Uros Potocnik7, Susanne Vijverberg6, Anna Nopp1, Caroline Nilsson1, and Erik Melén1

1Karolinska Institute
2University Medical Centre Groningen
3Astrid Lindgren Children’s Hospital
4University of Regensburg
5University of Amsterdam
6Amsterdam University Medical Centres
7University of Maribor

July 7, 2021

Transcriptome changes during peanut oral immunotherapy and omalizumab treatment

To the Editor,

Peanut allergy is a common food allergy and the main cause of anaphylaxis among children1. In recent years, oral immunotherapy has emerged as a promising treatment for children with different IgE-mediated food allergies, although safety issues must be considered2. The main aim of immunotherapy is to induce tolerance or desensitization to an allergen which otherwise causes an allergic reaction. For oral immunotherapy this means ingesting the allergen in a controlled manner with gradually increasing dosages. Specifically, peanut oral immunotherapy (pOIT) is able to induce tolerance/desensitization3. While the pathogenesis of food allergy in general is relatively well-studied4, mechanisms of OIT-induced tolerance are not well understood. Omalizumab (anti-IgE) used as treatment for severe allergic asthma and other IgE-driven allergies, can facilitate OIT initiation5, however, little is known about the involved mechanisms, including possible changes at the transcriptional level. We therefore investigated transcriptional changes in whole blood using RNA-sequencing profiles during omalizumab treatment and pOIT in participants from the FASTX (Food Allergen Suppression Therapy with Xolair®) study previously described in detail elsewhere5.

In brief, peanut-allergic adolescents (n=23 of whom 17 completed the study, age 12-18 years) were started on omalizumab (baseline) and treated for at least 8 weeks before starting pOIT (pOIT start) while on omalizumab. The peanut-dose was gradually increased during the 8 weeks until reaching a maintenance dose. Guided by a basophil activation test (BAT/CD-sens)6 after 8 weeks on the maintenance dose, participants decreased the omalizumab dose by 50% (maintenance) and continued to decrease the omalizumab dose if pOIT was tolerated. Eleven patients were able to tolerate pOIT without omalizumab protection for >8 weeks and then passed an open peanut food challenge (final); 6 patients could not discontinue omalizumab, but blood samples were obtained for analysis after 2-3 years of omalizumab treatment (final); 6 patients dropped out of the study. RNA-sequencing was performed on whole blood at baseline, pOIT start, maintenance and final time-points using the NovaSeq 6000 platform. DESeq2 was used for differential expression analysis of the omalizumab effect and a linear mixed-effect model for analyses during pOIT in combination with
omalizumab (pOIT+O) after adjustment for treatment outcome and cell type. A complete description of the treatment protocol and method is given in Appendix S1.

General characteristics of the study participants at baseline can be found in Table S1. To elucidate if omalizumab treatment alone induced alterations in peripheral blood gene expression, we investigated the two first timepoints, baseline and pOIT start, however no significant differences were observed (Figure S1). In the longitudinal analysis (pOIT start to final), 680 genes associated with pOIT+O at nominal p <0.005 (Table S2). The Gene Ontology (GO) biological process of the up- and down-regulation of these 680 genes are presented in Figure 1A,B. Upregulation of 337 genes were linked to GO terms “protein regulation and modification”, while “neutrophil degranulation, immune response, phagocytosis, and metabolic process” were among the top terms for the downregulated 343 genes. Out of the 680 genes, 16 were differentially expressed at false discovery rate (FDR) adjusted p<0.05 (Table 1, Figure S2). The three genes with the largest negative and positive coefficients, respectively, are displayed in Figure 1C,D: downregulation of \textit{ASGR2}, \textit{GPBAR1} and \textit{HM13}, and upregulation of \textit{USP44}, \textit{ICOS} and \textit{CDKN2AIP}. Finally, we evaluated the enrichment of 680 pOIT+O-associated genes, relative to peripheral blood gene expression associated with acute peanut allergic reactions in a recently published clinical study by Watson et al using the same p-value cut-off (p<0.005)\textsuperscript{7}. Out of our 680 significant genes, 108 genes overlapped with the differentially expressed genes in Watson et al\textsuperscript{7}, mostly with opposite direction, \(P_{\text{enrichment}} = 0.0095\) (Figure 2).

Our results demonstrate that omalizumab treatment alone does not induce alterations in whole blood gene expression in patients with severe food allergy. This is not surprising given that these patients were unexposed to peanut allergen at the time of blood sampling, and any concomitant asthma, rhinitis or eczema were well controlled. However, the longitudinal analysis during pOIT+O identified up- and downregulation of several immune-related genes. CD278/ICOS (Inducible T-cell costimulatory) is expressed on activated T-cells and appears to play a role in directing effector T-cell differentiation and responses during inflammatory conditions\textsuperscript{8}. ICOS-expression on T regulatory cells and T follicular helper cells may be involved in the allergic disease mechanism\textsuperscript{9}. In the pathway analyses, we observed significant enrichment for several GO biological process terms related to T-cell function and immune responses. Notably, we have previously described alterations in T-cell polyclonal \textit{in vitro} activation during pOIT+O in the FASTX study\textsuperscript{10}. Comparing our findings with data described by Watson et al\textsuperscript{7}, suggests that pOIT+O may alter the expression level of many genes that were found activated during an acute peanut allergy reaction.

The main limitations of this study are lack of any control subjects and small sample size. Moreover, further studies are needed to evaluate the long-term biological effect of pOIT+O.

In conclusion, omalizumab treatment alone does not alter the transcriptional signature in peripheral blood of peanut allergic patients, but during pOIT+O, several immune-related signatures were observed. These results may provide insights into mechanisms of allergen tolerance.

ACKNOWLEDGEMENTS

We thank all FASTX patients for their participation and the research staff at Forskningscentrum, Sodersjukhuset.

CONFLICT OF INTEREST

None.

ETHICAL APPROVAL

Approved by the ethics committee in Stockholm: 2013/827-31/3, 2014/1980-32, 2016/1390-32, 2020-00807 and the Swedish Drug Agency: 5.1-2013-46183; The trial is registered at EudraCT: 2012-005625-78, ClinicalTrials.gov; NCT02402231. Patients and caregivers provided written informed consent.

FUNDING
The PERMEABLE consortium, supported by ZonMW (456008004), the Swedish Research Council (2018-05619), the Ministry of Education, Science and Sport of the Republic of Slovenia (C3330-19-252012), the German Ministry of Education and Research (BMBF) (FKZ01KU1909A), under the frame of the ERA PerMed JTC 2018 Call. Additional funding in the Appendix.

Sophia Bjorkander
Simon Kebede Merid
David Brodin
Josef Brandstrom
Fredrik Fagerstrom-Billai
Marieke van der Heiden
Jon R Konradsen
Michael Kabesch
Cornelis M van Drunen
Korneliusz Golebski
Anke H Maitland-van der Zee
Uroš Potočnik
Susanne J H Vijverberg
Anna Nopp
Caroline Nilsson
Erik Melén

1. Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden
2. Bioinformatics and Expression Core Facility, Karolinska Institutet, Huddinge, Sweden
3. Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden
4. Astrid Lindgren Children’s Hospital, Karolinska University Hospital, Stockholm, Sweden
5. Department of Medical Microbiology and Infection Prevention, University Medical Centre Groningen, University of Groningen, The Netherlands
6. Department of Pediatric Pneumology and Allergy, University Children’s Hospital Regensburg (KUNO), Regensburg, Germany
7. Department of Otorhinolaryngology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
8. Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
9. Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
10. Faculty of Medicine, Center for Human Molecular Genetics and Pharmacogenomics, University of Maribor, Maribor, Slovenia
11. Laboratory for Biochemistry, Molecular Biology and Genomics, Faculty for Chemistry and Chemical Engineering, University of Maribor, Maribor, Slovenia
12. Sachs Children and Youth Hospital, Stockholm, Sweden

#Equal contribution
Correspondence

Professor Erik Melén
Telephone: +46-(0)8-524-875-08.
E-mail: erik.melen@ki.se

Key words: peanut allergy, oral immunotherapy, Omalizumab, Xolair, RNA-sequencing, gene expression, adolescences

REFERENCES

1 Vetander, M. et al. Anaphylaxis to foods in a population of adolescents: incidence, characteristics and associated risks. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 46, 1575-1587, doi:10.1111/cea.12842 (2016).

2 Chu, D. K. et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. The Lancet 393, 2222-2232, doi:https://doi.org/10.1016/S0140-6736(19)30420-9 (2019).

3 Fiocchi, A. et al. Oral immunotherapy for peanut allergy: The con argument. World Allergy Organization Journal 13, 100445, doi:https://doi.org/10.1016/j.waojou.2020.100445 (2020).

4 Ramsey, N. & Berin, M. C. Pathogenesis of IgE-mediated food allergy and implications for future immunotherapeutics. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, doi:10.1111/pai.13501 (2021).

5 Brandström, J. et al. Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 49, 1328-1341, doi:10.1111/cea.13469 (2019).

6 Nopp, A., Cardell, L. O., Johansson, S. G. & Oman, H. CD-sens: a biological measure of immunological changes stimulated by ASIT. Allergy 64, 811-814, doi:10.1111/j.1398-9995.2008.01900.x (2009).

7 Watson, C. T. et al. Integrative transcriptomic analysis reveals key drivers of acute peanut allergic reactions. Nature communications 8, 1943, doi:10.1038/s41467-017-02188-7 (2017).

8 Wikenheiser, D. J. & Stumhofer, J. S. ICOS Co-Stimulation: Friend or Foe? 7, doi:10.3389/fimmu.2016.00304 (2016).

9 Li, D. Y. & Xiong, X. Z. ICOS(+) Tregs: A Functional Subset of Tregs in Immune Diseases. Frontiers in immunology 11, 2104, doi:10.3389/fimmu.2020.02104 (2020).

10 van der Heiden, M. et al. A pilot study towards the immunological effects of omalizumab treatment used to facilitate oral immunotherapy in peanut-allergic adolescents. Scandinavian journal of immunology 93, e13005, doi:10.1111/sji.13005 (2021).

FIGURE LEGENDS

Figure 1. (A, B) Gene ontology (GO) biological process analysis of upregulated (A) and downregulated (B) genes. The x-axis shows the gene ratio of the overlapping genes of our gene list with the pathway gene set. The colour bar represents the adjusted p-value and the circle size is the count of overlapping genes.(C, D) Boxplots display log2 expression values for six pOIT genes (C: upregulated, D: downregulated) throughout the treatment protocol at FDR p<0.05. Red box: pOIT start, green box: Maintenance, blue box: Final. ORA = Over-representation analysis.

Figure 2. Overlap of 108 genes from the FASTX pOIT study with the peanut-related genes found in Watson et al., at nominal p<0.005. The y-axis represents changes in gene expression between the means at baseline and the four-hour time point of the peanut challenge in Watson et al., and the x-axis is effect size estimates from the mixed-effect model in the FASTX pOIT study. The green colour shows opposite direction, and the pink same direction.
Hosted file

PAI Table 1.docx available at https://authorea.com/users/424423/articles/529517-transcriptome-changes-during-peanut-oral-immunotherapy-and-omalizumab-treatment

Hosted file

PAI Figures 2021-06-30.pdf available at https://authorea.com/users/424423/articles/529517-transcriptome-changes-during-peanut-oral-immunotherapy-and-omalizumab-treatment